Amarin Corporation plc
http://www.amarincorp.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Amarin Corporation plc
Stock Watch: Rare Diseases Beget Rare Profitability
Do rare disease drugs with tiny patient populations lie outside the profitability continuum that runs from small-molecule primary care products to specialist biologics?
Vazkepa: ‘Constructive Discussions' Help Amarin Win Reimbursement For ‘Hundreds Of Thousands’ In UK
Amarin’s drug, which costs £144.21 for a 30-day supply, is to be made available on the National Health Service in England and Wales for reducing the risk of cardiovascular events after NICE reversed its previous rejection of the product.
Finance Watch: Resilience Raises $625m, Bringing New Cash To $1.2bn
The biomanufacturing firm National Resilience has raised more than $2bn in venture capital and millions more in fees from government and industry contracts since 2020. Also, Code Biotherapeutics raised $75m in series A cash, Concert grossed $66.4m and Amarin is cutting US jobs.
Repare Gets Cash And Validation In DNA Damage Repair Alliance With Roche
Roche is paying $125m upfront to in-license potential blockbuster lead candidate camonsertib from Repare, which calls it a best-in-class ATR inhibitor and has the chance to opt back in on US commercialization.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Amarin Pharma
- Amarin Pharmaceuticals Ireland Limited
- Laxdale Limited